Tomoharu Takeoka

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 300 citations

Medicine, Hematology, Oncology +4

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 117 citations · Full text

Medicine, Oncology, Pharmacology +9

Calpain-mediated X-linked Inhibitor of Apoptosis Degradation in Neutrophil Apoptosis and Its Impairment in Chronic Neutrophilic Leukemia

Susumu Kobayashi, Kouhei Yamashita, Tomoharu Takeoka et al. · Journal of Biological Chemistry · 2002 · 105 citations · Full text

Life Sciences, Hematology, Immunology +15

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai et al. · The Lancet Haematology · 2021 · 64 citations

Medicine, Hematology, Pharmacology +8

A novel potent tumour promoter aberrantly overexpressed in most human cancers

Atsushi Takahashi, Hisashi Tokita, Kenzo Takahashi et al. · Scientific Reports · 2011 · 33 citations · Full text

Medicine, Molecular Biology, Oncology +14